ALUR Overview

Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.

Wall Street analysts forecast ALUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALUR is6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Allurion Technologies Inc revenue for the last quarter amounts to 2.66M USD, decreased -50.48

Allurion Technologies Inc. EPS for the last quarter amounts to -1.53 USD, decreased -145.00

Allurion Technologies Inc (ALUR) has 134 emplpoyees as of March 17 2026.

Today ALUR has the market capitalization of 62.36M USD.